Projects per year
Fingerprint
Dive into the research topics where Longqin Hu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 8 Finished
-
HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
National Institute of Mental Health
12/3/10 → 11/30/12
Project: Research project
-
Optimization of EphA subtype-selective antagonists as probes for the nervous syst
National Institute on Alcohol Abuse and Alcoholism
9/30/09 → 8/31/10
Project: Research project
-
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction
9/25/08 → 7/31/09
Project: Research project
-
-
Development of convenient crystallization inhibition assays for structure-activity relationship studies in the discovery of crystallization inhibitors
Yang, J., Albanyan, H., Wang, Y., Yang, Y., Sahota, A. & Hu, L., Jul 2023, In: Medicinal Chemistry Research. 32, 7, p. 1391-1399 9 p.Research output: Contribution to journal › Article › peer-review
-
Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer
Xie, T., Zahid, H., Ali, A. R., Joyce, R., Yang, G., Winz, C., Le, Y., Zhou, R., Furmanski, P., Hu, L. & Suh, N., Feb 1 2023, In: Toxicology and Applied Pharmacology. 460, 116375.Research output: Contribution to journal › Article › peer-review
-
Optimization of the C2 substituents on the 1,4-bis(arylsulfonamido)naphthalene-N,N′-diacetic acid scaffold for better inhibition of Keap1-Nrf2 protein-protein interaction
Abed, D. A., Ali, A. R., Lee, S., Nguyen, M. U., Verzi, M. P. & Hu, L., Apr 5 2023, In: European Journal of Medicinal Chemistry. 252, 115302.Research output: Contribution to journal › Article › peer-review
-
Design, synthesis, and structure–activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway
Yang, J., Basu, S. & Hu, L., Oct 2022, In: Medicinal Chemistry Research. 31, 10, p. 1716-1739 24 p.Research output: Contribution to journal › Article › peer-review
-
Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
Wang, J., Lam, D., Yang, J. & Hu, L., Oct 2022, In: Medicinal Chemistry Research. 31, 10, p. 1647-1662 16 p.Research output: Contribution to journal › Review article › peer-review
Open Access